Renaissance Technologies’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-185,000
| Closed | -$7.35M | – | 3250 |
|
|
2026
Q1 | $7.35M | Sell |
185,000
-94,300
| -34% | -$2.41M | 0.01% | 1150 |
|
|
2025
Q4 | $6.99M | Buy |
279,300
+114,700
| +70% | +$2.91M | 0.01% | 1110 |
|
|
2025
Q3 | $3.99M | Sell |
164,600
-220,300
| -57% | -$3.92M | 0.01% | 1629 |
|
|
2025
Q2 | $5.06M | Buy |
384,900
+206,900
| +116% | +$2.62M | 0.01% | 1522 |
|
|
2025
Q1 | $2.56M | Sell |
178,000
-600
| -0.3% | -$9.82K | ﹤0.01% | 1847 |
|
|
2024
Q4 | $2.99M | Sell |
178,600
-31,000
| -15% | -$514K | ﹤0.01% | 1780 |
|
|
2024
Q3 | $3.35M | Buy |
209,600
+35,900
| +21% | +$440K | 0.01% | 1699 |
|
|
2024
Q2 | $1.57M | Sell |
173,700
-45,100
| -21% | -$428K | ﹤0.01% | 2028 |
|
|
2024
Q1 | $2.47M | Buy |
218,800
+33,200
| +18% | +$314K | ﹤0.01% | 1891 |
|
|
2023
Q4 | $1.48M | Buy |
185,600
+132,500
| +250% | +$888K | ﹤0.01% | 2147 |
|
|
2023
Q3 | $344K | Buy |
53,100
+18,800
| +55% | +$129K | ﹤0.01% | 2869 |
|
|
2023
Q2 | $212K | Buy |
34,300
+18,600
| +118% | +$88.2K | ﹤0.01% | 3281 |
|
|
2023
Q1 | $60K | Buy |
+15,700
| New | +$57.4K | ﹤0.01% | 3616 |
|
Renaissance Technologies's CNTA Position: Q2 2026 in Review
Renaissance Technologies sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 185,000 shares — an estimated $7.35M sold.
Renaissance Technologies first reported a position in CNTA in Q1 2023 and held it in 13 quarters. The position peaked at $7.35M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Renaissance Technologies reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Renaissance Technologies sold 185,000 Centessa Pharmaceuticals shares in Q2 2026, an estimated $7.35M.
- Renaissance Technologies first reported a position in Centessa Pharmaceuticals in Q1 2023 and held it in 13 quarters.
- Renaissance Technologies's Centessa Pharmaceuticals position peaked at $7.35M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.